相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Health-related quality of life of multiple sclerosis patients: a European multi-country study
Laurenske A. Visser et al.
ARCHIVES OF PUBLIC HEALTH (2021)
Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review
L. A. Visser et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
Chiara Whichello et al.
HEALTH POLICY (2020)
Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences
Louis S. Matza et al.
QUALITY OF LIFE RESEARCH (2019)
Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF
Sumonto Mitra et al.
FRONTIERS IN NEUROSCIENCE (2019)
Severity-Adjusted Probability of Being Cost Effective
Matthijs M. Versteegh et al.
PHARMACOECONOMICS (2019)
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Renee Else Michels et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2019)
Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Mitchell T. Wallin et al.
LANCET NEUROLOGY (2019)
3D cell-laden polymers to release bioactive products in the eye
Gorka Orive et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2019)
Health state utilities associated with post-surgical Staphylococcus aureus infections
Louis S. Matza et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
Sergio Iannazzo et al.
PHARMACOECONOMICS (2018)
Current advanced therapy cell-based medicinal products for type-1-diabetes treatment
Alberto Canibano-Hernandez et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
Jing Chen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations
Luis Hernandez et al.
PHARMACOECONOMICS (2018)
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group
Peter Rieckmann et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
Laura Barin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
Duygu Bozkaya et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Evolving concepts in the treatment of relapsing multiple sclerosis
Giancarlo Comi et al.
LANCET (2017)
Diagnosis of multiple sclerosis: progress and challenges
Wallace J. Brownlee et al.
LANCET (2017)
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
Bernard Uitdehaag et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
Maarten J. IJzerman et al.
PHARMACOECONOMICS (2017)
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
Bernard Uitdehaag et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies
Pascale Lehoux et al.
INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT (2017)
Cost-utility of First-line Disease-modifying Treatments for Relapsing Remitting Multiple Sclerosis
Erkki Soini et al.
CLINICAL THERAPEUTICS (2017)
Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room
Tim A. Kanters et al.
EUROPACE (2016)
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Jens Ingwersen et al.
NEUROTHERAPEUTICS (2016)
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
P. Vemer et al.
PHARMACOECONOMICS (2016)
The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
Luis Hernandez et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Emer Fogarty et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
Julie Chevalier et al.
PLOS ONE (2016)
Commercial viability of medical devices using Headroom and return on investment calculation
Katarzyna Markiewicz et al.
TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE (2016)
The iMTA Productivity Cost Questionnaire A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses
Clazien Bouwmans et al.
VALUE IN HEALTH (2015)
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-beta(1a) in Relapsing-Remitting Multiple Sclerosis
Xinke Zhang et al.
CNS DRUGS (2015)
Health state utilities associated with attributes of treatments for hepatitis C
Louis S. Matza et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2015)
Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant
Marc Folcher et al.
NATURE COMMUNICATIONS (2014)
A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis
Sarah Acaster et al.
BMC HEALTH SERVICES RESEARCH (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence
G. Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
Hiangkiat Tan et al.
ADVANCES IN THERAPY (2011)
Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients
George P. Christophi et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
Kristina S. Boye et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2011)
Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis A Non-Experimental, Retrospective, Cohort Study
Stephanie C. Steinberg et al.
CLINICAL DRUG INVESTIGATION (2010)
Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria
S. E. Hofer et al.
PEDIATRIC DIABETES (2010)
Full results of the evidence of interferon dose-response-European north American comparative efficacy (EVIDENCE) study:: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis
Steven R. Schwid et al.
CLINICAL THERAPEUTICS (2007)
The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK
Michelle Orme et al.
VALUE IN HEALTH (2007)
Preference-based EQ-5D index scores for chronic conditions in the United States
Patrick W. Sullivan et al.
MEDICAL DECISION MAKING (2006)
Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status
A Miller et al.
QUALITY OF LIFE RESEARCH (2006)
A review about the impact of multiple sclerosis on health-related quality of life
J Benito-León et al.
DISABILITY AND REHABILITATION (2003)
分享论文
